Key result
Intensive SBP control cuts MACE ~18% versus standard targets without increasing serious adverse events.
Why the study?
Conflicting trial results and recent safety concerns have left optimal systolic blood pressure targets and the balance of benefits and harms uncertain, including in patients with diabetes.
Does intensive systolic blood pressure treatment reduce major adverse cardiovascular events compared to standard systolic blood pressure treatment in patients with hypertension, including those with diabetes?
Meta-Analysis (n=50,070)
Does intensive systolic blood pressure treatment reduce major adverse cardiovascular events compared to standard systolic blood pressure treatment in patients with hypertension, including those with diabetes?
Intensive systolic blood pressure targets significantly reduce major adverse cardiovascular events, mortality, heart failure, MI, and stroke—particularly in non-diabetic patients—at the expense of increased risks of hypotension, syncope, renal failure, and electrolyte abnormalities.
Intensive SBP targets merit consideration in high-risk hypertension; reinforces SPRINT benefits across broader populations with manageable adverse events.
Background/Introduction Hypertension is a major cardiovascular risk factor. While SPRINT supported systolic blood pressure (SBP) <120 mmHg, ACCORD showed no similar benefit in diabetes. Recent trials raised safety concerns, leaving optimal SBP targets and the benefit-harm balance uncertain. Purpose To evaluate the efficacy and safety of intensive versus standard SBP targets for major adverse cardiovascular events (MACE) and serious adverse events (SAE), including in diabetic patients. Methods This PRISMA/PROSPERO systematic review searched five databases up to Jan 2026. We included 12 trials. Bias was assessed via Cochrane RoB 2. Random-effects meta-analyses estimated risk ratios (RR) with 95% confidence and prediction intervals (PI). Risk differences and numbers needed to harm (NNH) were calculated for SAEs. Analyses used Stata 19.0. Results Across 12 trials (50,070 patients; follow-up 2.0–4.7 years), intensive SBP control reduced MACE (RR 0.82; 95% CI 0.77–0.87; I²=40.9%; post-sensitivity RR 0.81; 0.76–0.87; I²=16.5%). Consistent reductions (I²≤13.0%) occurred in cardiovascular (CV) mortality (RR 0.71; 0.61–0.83), heart failure (RR 0.71; 0.61–0.83), myocardial infarction (MI) (RR 0.83; 0.73–0.94), and stroke (RR 0.80; 0.73–0.87), but not acute coronary syndrome (RR 0.93; 0.83–1.04). Benefit was independent of measurement method (automated vs. observed, p-int=0.646). Stroke decreased in diabetic (RR 0.72; 0.54–0.97) and non-diabetic (RR 0.82; 0.73–0.92) patients; however, MI (RR 0.80; 0.69–0.94) and CV mortality (RR 0.63; 0.52–0.76) reductions were exclusive to non-diabetics (p-int=0.641). Safety: intensive therapy increased hypotension (RR 2.34; 1.47–3.72; PI 0.91–5.99; NNH 94), renal failure (RR 1.67; 1.24–2.24; PI 1.08–2.58; NNH 240), syncope (RR 1.71; 1.28–2.28; PI 1.10–2.65; NNH 289), hyponatraemia (RR 1.44; 1.03–2.00; PI 0.81–2.56; NNH 184), and hypokalaemia (RR 1.30; 1.09–1.54). Overall SAEs (RR 1.01; 0.98–1.04; PI 0.98–1.04), arrhythmias (RR 1.13; 0.76–1.69), and falls (RR 0.98; 0.87–1.11) did not significantly increase. Conclusion(s) Intensive SBP targets offer substantial cardiovascular protection, mainly for non-diabetics, but require a clinical trade-off. While overall SAEs remain stable, elevated risks of hypotension, syncope, and renal failure mandate personalised, closely monitored treatment
No takes yet. Share an insight, caveat, or question.
Ochoa et al. (2026) conducted a meta-analysis in Hypertension (n=50,070). Intensive systolic blood pressure treatment vs. Standard systolic blood pressure treatment was evaluated on Major adverse cardiovascular events (MACE) (RR 0.82, 95% CI 0.77-0.87). Intensive systolic blood pressure control reduced major adverse cardiovascular events compared to standard targets (RR 0.82; 95% CI 0.77–0.87) without increasing overall serious adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: